Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa

AIDS

Volumn 24, Issue 11, 2010, Pages 1709-1716

  Hoffmann, Christopher J ^a,b   Fielding, Katherine L ^c   Charalambous, Salome ^a   Innes, Craig ^a   Chaisson, Richard E ^b   Grant, Alison D ^c   Churchyard, Gavin J ^a,c  

^a AURUM INSTITUTE   (South Africa)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; antiretroviral therapy; cotrimoxazole; HIV; mortality

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; ISONIAZID; LAMIVUDINE PLUS STAVUDINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALARIA; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; SOUTH AFRICA; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 77954336897     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ac6bc     Document Type: Article

References (24)

1. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58 (RR-11):1-166.
2. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxa-zole for HIV-1-infected adults in Abidjan, Cote d?Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463-1468.
3. MerminJ, Lule J, Ekwaru JP, MalambaS, DowningR, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-1434.
4. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d?Ivoire: a randomised controlled trial. Lancet 1999; 353:1469-1475.
5. Sesay M, Chimzizi R, Chotpitayasunondh T, Crowley S, Duncombe C, El Sadr W, et al. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents, and adults in resource-limited settings. Geneva, Switzerland: World Health Organization; 2006.
6. Lynen L, Jacobs J, Colebunders R. Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough? TransR Soc Trop Med Hyg 2007; 101:1059-1060.
7. Anglaret X, Sylla-Koko F, Bonard D, Combe P, Coulibaly M, Aoussi E, et al. Susceptibilities to co-trimoxazole of pathogens isolated from blood and stool specimens in Abidjan, Ivory Coast, 1994 to 1996. J Clin Microbiol 1997; 35:1915.
8. Nchabeleng M. Cotrimoxazole resistance amongst commensal organisms in AIDS patients commencing cotrimoxazole prophylaxis [abstract #T1-S3-A14]. First South African AIDS Conference; Durban, South Africa; 2003.
9. Group for Enteric Respiratory and Meningeal Disease Surveillance in South Africa. In: Govender N, Cohen C, editors. GERMS-SA Annual Report 2008. South Africa: NICD; 2008.
10. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
11. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
12. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
13. Lawn SD, Myer L, Bekker LG, WoodR. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006; 6:59.
14. Pemba L, Charalambous S, von GA, Magadla B, Moloi V, Seabi O, et al. Impact of cotrimoxazole on nonsusceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. J Infect 2008; 56:171-178.
15. Crewe-Brown HH, Reyneke MP, Khoosal M, Becker PJ, Kar-staedt AS. Increase in trimethoprim-sulphamethoxazole (co-trimoxazole) resistance at Chris Hani Baragwanath Hospital, Soweto, in the AIDS era. S Afr Med J 2004; 94:440-442.
16. Liebowitz LD, Slabbert M, Huisamen A. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents. J Clin Pathol 2003; 56:344-347.
17. Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007; 21:2043-2050.
18. Murray J, Sonnenberg P, Nelson G, Bester A, Shearer S, Glynn JR. Cause of death and presence of respiratory disease at autopsy in an HIV-1 seroconversion cohort of southern African gold miners. AIDS 2007; 21 (Suppl 6):S97-S104.
19. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimox-azole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001; 15:1143-1148.
20. Zachariah R, Spielmann MP, Chinji C, Gomani P, Arendt V, Hargreaves NJ, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003; 17:1053-1061.
21. Nunn AJ, Mwaba P, Chintu C, MwingaA, Darbyshire JH, Zumla A. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008; 337:a257.
22. Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, Eiger O, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 2007; 46:56-61.
23. Mzileni MO, Longo-Mbenza B, Chephe TJ. Mortality and causes of death in HIV-positive patients receiving antiretrovir-al therapy at Tshepang Clinic in Doctor George Mukhari Hospital. Pol Arch Med Wewn 2008; 118:548-554.
24. Garcia-Jardon M, Bhat VG, Blanco-Blanco E, Stepian A. Postmortem findings in HIV/AIDS patients in a tertiary care hospital in rural South Africa. Trop Doct 2010; 40:81-84.